医学
塞库金单抗
皮肤病科
斑块性银屑病
恶化
杜皮鲁玛
银屑病
特应性皮炎
湿疹性皮炎
不利影响
免疫学
内科学
银屑病性关节炎
作者
Melissa Peri Zundell,Alice Bendix Gottlieb,Roselyn Stanger
摘要
Paradoxical reactions to biologic agents used in the treatment of psoriasis are rare but have been reported with tumor necrosis factor (TNF) blockers and, more recently, with interleukin (IL)-17A inhibitors. Secukinumab, an IL-17A inhibitor, is an effective treatment for moderate-to-severe plaque psoriasis but has been implicated in the development or exacerbation of eczematous-like reactions in rare cases. We present a patient with a history of plaque psoriasis who developed an eczematous eruption after four months of secukinumab therapy, necessitating systemic intervention for adequate control. Five months after a loading dose of dupilumab, the patient appeared in the clinic with the return of classic, thick psoriatic plaques, affecting 15% BSA. The patient declined further treatment and was subsequently lost to follow-up despite multiple attempts to contact her. This case adds to the limited, but growing body of knowledge on IL-17 blocker-induced eczematous reactions and underscores the need for careful monitoring and prompt recognition of this adverse event in patients receiving this class of drugs. J Drugs Dermatol. 2024;23(2):97-99. doi:10.36849/JDD.7639 .
科研通智能强力驱动
Strongly Powered by AbleSci AI